OBIO

Orchestra BioMed Holdings, Inc.

Healthcare · $356M market cap

We can't put a fair value on OBIO right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?

Equity per share growth-16.6% a year✗

Sales growth5.9% a year✗

Free cash flow growth—?

Return on invested capital-51.8%✗

Follow OBIO

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Sep 1, 2026: 1 open-market purchase worth $48K, 1 sale worth $74K and 1 other filing (stock awards, tax withholding and similar). Why purchases matter

Purchases

Hochman David P

See Remarks · 2026-09-03

Bought

$48K

Sales

Sherman Darren

See Remarks · 2026-09-01

Sold

$74K

Other filings

Hochman David P

See Remarks · 2026-09-10

Tax withholding

$19K

About Orchestra BioMed Holdings, Inc.

Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease. The company's offerings also encompass FreeHold retractors, which are solutions for minimally invasive…

Biotechnology